Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer

Area of Science:

• Immunology
• Oncology
• Cancer Therapy

Background:

• Malignant tumor cells possess mechanisms to evade host immune surveillance.
• Immune checkpoint molecules, such as programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1), mediate immunosuppression in antitumor immunity by delivering coinhibitory signals to immune cells.
• PD-1 and PD-L1 are critical targets for novel cancer therapies.

Approach:

• This review synthesizes recent advancements in targeting PD-1 and PD-L1 pathways.
• Focuses on the application of these targeted therapies in gastric cancer (GC).
• Examines the clinical development and approved antibody-based treatments.

Key Points:

• PD-1/PD-L1 interactions are crucial for immune evasion by cancer cells.
• Antibodies targeting PD-1 and PD-L1 have demonstrated efficacy in various cancers.
• Recent developments highlight their potential in overcoming immunosuppression in gastric cancer.

Conclusions:

• Targeting PD-1 and PD-L1 represents a significant breakthrough in cancer immunotherapy.
• The review underscores the evolving landscape of PD-1/PD-L1-based treatments for gastric cancer.
• Further research into optimizing these therapies for improved patient outcomes is warranted.